Literature DB >> 7583170

Molecular biology of myocardial hypertrophy and failure: gene expression and trophic signaling.

T G Parker1.   

Abstract

Pressure-overload cardiac hypertrophy is associated with the re-expression of an ensemble of genes representative of embryonic myocardium, whose protein products modulate myocardial function. Regulation of cardiac-specific gene expression in end-stage myocardial disease in humans implies a pathophysiologic role for altered gene expression in the progression from compensatory hypertrophy to decompensated heart failure. The molecular signals that transduce load into a hypertrophic cardiac myocyte phenotype involve mechanical deformation and the local myocardial production of trophic factors, including angiotensin II, and transforming and fibroblast growth factors. Growth factors provoke a pattern of gene expression in cultured cardiac myocytes resembling that seen in pressure overload in vivo, in keeping with an autocrine or paracrine model of hypertrophy. Moreover, growth factor stimulation and pressure-overload hypertrophy share intracellular signaling pathways, including the activation of nuclear proteins encoded by cellular oncogenes. Elucidation of these signaling pathways may provide new therapeutic targets for the treatment of cardiac muscle disease that overcomes the limitations of currently available strategies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7583170

Source DB:  PubMed          Journal:  New Horiz        ISSN: 1063-7389


  2 in total

1.  Modulation of MLC-2v gene expression by AP-1: complex regulatory role of Jun in cardiac myocytes.

Authors:  S K Goswami; S Shafiq; M A Siddiqui
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

2.  The role of angiotensin II, endothelin-1 and transforming growth factor-beta as autocrine/paracrine mediators of stretch-induced cardiomyocyte hypertrophy.

Authors:  A J van Wamel; C Ruwhof; L E van der Valk-Kokshoom; P I Schrier; A van der Laarse
Journal:  Mol Cell Biochem       Date:  2001-02       Impact factor: 3.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.